60MO Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN

      MONSTAR-SCREEN is the nationwide cancer genome screening project of prospectively assessing gut microbiota and circulating tumor DNA in 2,000 pts with advanced solid tumor at 31 Japanese institutions. Recently, several studies have showed that gut microbiota modulates efficacy of ICIs across cancer types. Here we report an initial analysis of association between alpha diversity index (ADI) of fecal microbiome and efficacy of ICIs between Sep 2019 and Sep 2020.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      ESMO Member Login

      Full access to the journal is a member benefit for ESMO Members, Login via the ESMO website to access all journal content.


      Subscribe to Annals of Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect